| Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (NCT01544595) | Novartis Pharmaceuticals | 2012-06-19 |
| Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. (NCT01623596) | Novartis Pharmaceuticals | 2012-06-08 |
| Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (NCT01597908) | Novartis Pharmaceuticals | 2012-06-04 |
| Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients (NCT01632358) | Novartis Pharmaceuticals | 2012-06-01 |
| Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool. (NCT01744028) | Novartis Pharmaceuticals | 2012-06-01 |
| A Phase I Study of LFA102 in Japanese Patients (NCT01610050) | Novartis Pharmaceuticals | 2012-06-01 |
| Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) (NCT01634763) | Novartis Pharmaceuticals | 2012-06-01 |
| First in Human Trial of TAS266 in Patients With Advanced Solid Tumors (NCT01529307) | Novartis Pharmaceuticals | 2012-06-01 |
| Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01613326) | Novartis Pharmaceuticals | 2012-06-01 |
| 4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (NCT01626222) | Novartis Pharmaceuticals | 2012-06-01 |
| A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients (NCT01576380) | Novartis Pharmaceuticals | 2012-06-01 |
| Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension (NCT01599104) | Novartis Pharmaceuticals | 2012-06-01 |
| A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia (NCT01594983) | Novartis Pharmaceuticals | 2012-06-01 |
| Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis (NCT02907281) | Novartis Pharmaceuticals | 2012-05-29 |
| Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients (NCT01551212) | Novartis Pharmaceuticals | 2012-05-24 |
| Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib (NCT01514448) | Novartis Pharmaceuticals | 2012-05-21 |
| Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (NCT01590199) | Novartis Pharmaceuticals | 2012-05-18 |
| First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (NCT01555125) | Novartis Pharmaceuticals | 2012-05-08 |
| A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma (NCT01584648) | Novartis Pharmaceuticals | 2012-05-04 |
| A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers (NCT01578928) | Novartis Pharmaceuticals | 2012-05-01 |
| Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors (NCT01596647) | Novartis Pharmaceuticals | 2012-05-01 |
| Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (NCT01604278) | Novartis Pharmaceuticals | 2012-05-01 |
| Pharmacokinetics of LCQ908 in Patients With Renal Impairment (NCT01558323) | Novartis Pharmaceuticals | 2012-05-01 |
| Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction (NCT01593787) | Novartis Pharmaceuticals | 2012-05-01 |
| The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01574651) | Novartis Pharmaceuticals | 2012-05-01 |
| Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (NCT01558739) | Novartis Pharmaceuticals | 2012-05-01 |
| Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (NCT01580020) | Novartis Pharmaceuticals | 2012-05-01 |
| Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01529632) | Novartis Pharmaceuticals | 2012-05-01 |
| Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (NCT01599650) | Novartis Pharmaceuticals | 2012-05-01 |
| STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) (NCT01585298) | Novartis Pharmaceuticals | 2012-04-29 |
| A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT01456689) | Novartis Pharmaceuticals | 2012-04-25 |
| MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) (NCT01643850) | Novartis Pharmaceuticals | 2012-04-23 |
| A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (NCT01468688) | Novartis Pharmaceuticals | 2012-04-20 |
| Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma (NCT01545817) | Novartis Pharmaceuticals | 2012-04-19 |
| A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment (NCT01610336) | Novartis Pharmaceuticals | 2012-04-05 |
| Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (NCT01220648) | Novartis Pharmaceuticals | 2012-04-01 |
| Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment (NCT01599637) | Novartis Pharmaceuticals | 2012-04-01 |
| 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension (NCT01570686) | Novartis Pharmaceuticals | 2012-04-01 |
| Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus (NCT01582230) | Novartis Pharmaceuticals | 2012-04-01 |
| Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (NCT02123199) | Novartis Pharmaceuticals | 2012-04-01 |
| Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment (NCT01594957) | Novartis Pharmaceuticals | 2012-04-01 |
| Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (NCT01513460) | Novartis Pharmaceuticals | 2012-04-01 |
| Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01491529) | Novartis Pharmaceuticals | 2012-04-01 |
| Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) (NCT01365468) | Novartis Pharmaceuticals | 2012-04-01 |
| Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer (NCT01528345) | Novartis Pharmaceuticals | 2012-04-01 |
| VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus (NCT01528254) | Novartis Pharmaceuticals | 2012-03-30 |
| Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (NCT01524783) | Novartis Pharmaceuticals | 2012-03-30 |
| Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease (NCT01562041) | Novartis Pharmaceuticals | 2012-03-09 |
| Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure (NCT01543854) | Novartis Pharmaceuticals | 2012-03-01 |
| Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma (NCT01478360) | Novartis Pharmaceuticals | 2012-03-01 |
| Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (NCT01566604) | Novartis Pharmaceuticals | 2012-03-01 |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) (NCT01520922) | Novartis Pharmaceuticals | 2012-03-01 |
| Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS) (NCT01482143) | Novartis Pharmaceuticals | 2012-03-01 |
| A Prospective, Open Label Study of CERtican in KIdney Transplantation (NCT01594268) | Novartis Pharmaceuticals | 2012-03-01 |
| Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 (NCT01619332) | Novartis Pharmaceuticals | 2012-03-01 |
| BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer (NCT01288092) | Novartis Pharmaceuticals | 2012-03-01 |
| Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias (NCT01491932) | Novartis Pharmaceuticals | 2012-03-01 |
| Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors (NCT01529619) | Novartis Pharmaceuticals | 2012-03-01 |
| BEZ235 Trial in Patients With Advanced Endometrial Carcinoma (NCT01290406) | Novartis Pharmaceuticals | 2012-03-01 |
| Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients (NCT01487785) | Novartis Pharmaceuticals | 2012-03-01 |
| Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (NCT01596062) | Novartis Pharmaceuticals | 2012-03-01 |
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors (NCT01324479) | Novartis Pharmaceuticals | 2012-02-29 |
| Continuation Study of the Oral AKT Inhibitor GSK2110183 (NCT01531894) | Novartis Pharmaceuticals | 2012-02-08 |
| Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD) (NCT01535950) | Novartis Pharmaceuticals | 2012-02-01 |
| A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors (NCT01546428) | Novartis Pharmaceuticals | 2012-02-01 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis (NCT01433250) | Novartis Pharmaceuticals | 2012-02-01 |
| A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab (NCT01471847) | Novartis Pharmaceuticals | 2012-02-01 |
| Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg (NCT01539213) | Novartis Pharmaceuticals | 2012-02-01 |
| Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (NCT01404325) | Novartis Pharmaceuticals | 2012-02-01 |
| Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients. (NCT01541189) | Novartis Pharmaceuticals | 2012-02-01 |
| Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (NCT01535261) | Novartis Pharmaceuticals | 2012-02-01 |
| A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma (NCT01479595) | Novartis Pharmaceuticals | 2012-02-01 |
| Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (NCT01497262) | Novartis Pharmaceuticals | 2012-02-01 |
| Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION) (NCT01541956) | Novartis Pharmaceuticals | 2012-02-01 |
| Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (NCT01555138) | Novartis Pharmaceuticals | 2012-02-01 |
| Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) (NCT01546532) | Novartis Pharmaceuticals | 2012-02-01 |
| Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma (NCT01545726) | Novartis Pharmaceuticals | 2012-02-01 |
| Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer (NCT01495247) | Novartis Pharmaceuticals | 2012-01-30 |
| Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) (NCT01527500) | Novartis Pharmaceuticals | 2012-01-25 |
| Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (NCT01576367) | Novartis Pharmaceuticals | 2012-01-16 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (NCT01552629) | Novartis Pharmaceuticals | 2012-01-05 |
| Safety and Efficacy of SAF312 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions (NCT01598103) | Novartis Pharmaceuticals | 2012-01-01 |
| Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT01543828) | Novartis Pharmaceuticals | 2012-01-01 |
| Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis (NCT01519661) | Novartis Pharmaceuticals | 2012-01-01 |
| Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection (NCT01524341) | Novartis Pharmaceuticals | 2012-01-01 |
| Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors (NCT01482156) | Novartis Pharmaceuticals | 2012-01-01 |
| Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency (NCT01337752) | Novartis Pharmaceuticals | 2012-01-01 |
| Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (NCT01534182) | Novartis Pharmaceuticals | 2012-01-01 |
| Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications (NCT01518101) | Novartis Pharmaceuticals | 2012-01-01 |
| A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults (NCT01601600) | Novartis Pharmaceuticals | 2012-01-01 |
| Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients (NCT01537432) | Novartis Pharmaceuticals | 2012-01-01 |
| Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (NCT01551173) | Novartis Pharmaceuticals | 2012-01-01 |
| Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy (NCT01456676) | Novartis Pharmaceuticals | 2012-01-01 |
| Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (NCT01478373) | Novartis Pharmaceuticals | 2012-01-01 |
| A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma (NCT01473901) | Novartis Pharmaceuticals | 2011-12-30 |
| Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (NCT01498887) | Novartis Pharmaceuticals | 2011-12-24 |
| Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients (NCT01430416) | Novartis Pharmaceuticals | 2011-12-20 |
| Observation of Treatment Patterns With Lucentis in Approved Indications (NCT02194803) | Novartis Pharmaceuticals | 2011-12-08 |
| Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study (NCT01326845) | Novartis Pharmaceuticals | 2011-12-01 |